CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Trade Novartis Adr Repsg 1 - USD - NVS CFD

98.77
1.87%
0.20
Low: 98.3
High: 98.81
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.20
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.025457%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.003235%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Novartis AG ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 96.96
Open* 98.43
1-Year Change* 9.79%
Day's Range* 98.3 - 98.81
52 wk Range 74.09-105.56
Average Volume (10 days) 2.51M
Average Volume (3 months) 46.42M
Market Cap 224.83B
P/E Ratio 30.45
Shares Outstanding 2.10B
Revenue 52.14B
EPS 3.25
Dividend (Yield %) 3.53726
Beta 0.54
Next Earnings Date Jul 18, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 2, 2023 98.77 0.70 0.71% 98.07 98.89 97.57
Jun 1, 2023 96.96 0.03 0.03% 96.93 97.13 96.20
May 31, 2023 96.13 0.00 0.00% 96.13 96.46 95.15
May 30, 2023 96.29 -0.49 -0.51% 96.78 96.84 96.00
May 26, 2023 97.77 -0.34 -0.35% 98.11 98.78 97.52
May 25, 2023 97.68 -0.77 -0.78% 98.45 98.54 97.21
May 24, 2023 99.77 -0.36 -0.36% 100.13 100.19 99.06
May 23, 2023 100.16 -1.26 -1.24% 101.42 101.42 99.96
May 22, 2023 100.69 -0.76 -0.75% 101.45 101.96 100.45
May 19, 2023 100.78 0.79 0.79% 99.99 100.96 99.97
May 18, 2023 100.12 -0.09 -0.09% 100.21 101.01 99.44
May 17, 2023 100.97 -1.19 -1.16% 102.16 102.23 100.62
May 16, 2023 102.54 -0.56 -0.54% 103.10 103.18 102.50
May 15, 2023 102.83 -0.40 -0.39% 103.23 103.45 102.53
May 12, 2023 103.07 0.02 0.02% 103.05 103.75 102.62
May 11, 2023 103.31 0.17 0.16% 103.14 103.53 102.65
May 10, 2023 103.57 0.00 0.00% 103.57 103.83 102.62
May 9, 2023 104.63 0.18 0.17% 104.45 104.89 104.05
May 8, 2023 104.64 0.07 0.07% 104.57 105.31 104.00
May 5, 2023 104.67 0.96 0.93% 103.71 104.85 103.35

Novartis Adr Repsg 1 - USD Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 51742 52877 49898 48624 46017
Revenue 51742 52877 49898 48624 46017
Cost of Revenue, Total 14998 15435 14400 13930 13555
Gross Profit 36744 37442 35498 34694 32462
Total Operating Expense 42545 41188 39746 39538 31824
Selling/General/Admin. Expenses, Total 14190 14815 14093 14319 13690
Research & Development 9088 9041 8484 8386 8154
Depreciation / Amortization 158 109 64 50 179
Unusual Expense (Income) 3402 1173 2503 2284 -4309
Other Operating Expenses, Total 449 653 538 607 549
Operating Income 9197 11689 10152 9086 14193
Interest Income (Expense), Net Non-Operating -543 14628 -146 -36 -5
Other, Net -283 -180 -128 -110 -93
Net Income Before Taxes 8371 26137 9878 8940 14095
Net Income After Taxes 6955 24018 8071 7147 12800
Minority Interest 0 3 1 -5 -3
Net Income Before Extra. Items 6955 24021 8072 7142 12797
Net Income 6955 24021 8072 11732 12611
Income Available to Common Excl. Extra. Items 6955 24021 8072 7142 12797
Income Available to Common Incl. Extra. Items 6955 24021 8072 11732 12611
Dilution Adjustment
Diluted Net Income 6955 24021 8072 11732 12611
Diluted Weighted Average Shares 2197 2260 2296 2319 2344
Diluted EPS Excluding Extraordinary Items 3.16568 10.6288 3.51568 3.07978 5.45947
Dividends per Share - Common Stock Primary Issue 3.32525 3.19907 3.08737 2.83413 2.93645
Diluted Normalized EPS 4.47075 11.1183 4.40641 3.86715 3.79006
Total Extraordinary Items 4590 -186
Interest Expense (Income) - Net Operating 260 -38 -336 -38 6
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 13208 13001 12842 13085 12814
Revenue 13208 13001 12842 13085 12814
Cost of Revenue, Total 3829 3837 3657 3749 3755
Gross Profit 9379 9164 9185 9336 9059
Total Operating Expense 10352 11052 10674 10857 9962
Selling/General/Admin. Expenses, Total 3401 3699 3404 3589 3498
Research & Development 2272 2318 2263 2251 2256
Depreciation / Amortization 153 42 42 39 35
Interest Expense (Income) - Net Operating 46 -28 90 96 102
Unusual Expense (Income) 298 1145 1068 996 295
Other Operating Expenses, Total 353 39 150 137 21
Operating Income 2856 1949 2168 2228 2852
Interest Income (Expense), Net Non-Operating -212 -222 -219 -202 -203
Other, Net 96 14 -30 16 20
Net Income Before Taxes 2740 1741 1919 2042 2669
Net Income After Taxes 2294 1466 1575 1695 2219
Minority Interest -1 0 -2 -1 3
Net Income Before Extra. Items 2293 1466 1573 1694 2222
Net Income 2293 1466 1573 1694 2222
Income Available to Common Excl. Extra. Items 2293 1466 1573 1694 2222
Income Available to Common Incl. Extra. Items 2293 1466 1573 1694 2222
Diluted Net Income 2293 1466 1573 1694 2222
Diluted Weighted Average Shares 2120 2158 2180 2211 2237
Diluted EPS Excluding Extraordinary Items 1.0816 0.67933 0.72156 0.76617 0.99329
Dividends per Share - Common Stock Primary Issue 0 3.32525 0 0 0
Diluted Normalized EPS 1.20956 1.14055 1.12553 1.14122 1.10442
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 36910 45718 29673 29504 35563
Cash and Short Term Investments 18726 28113 11293 11234 15718
Cash 2877 3396 3750 3247 3121
Cash & Equivalents 4640 9011 5908 7865 10150
Short Term Investments 11209 15706 1635 122 2447
Total Receivables, Net 9894 9621 10036 10337 11036
Accounts Receivable - Trade, Net 8066 8005 8217 8301 8739
Total Inventory 7175 6666 7131 5982 6956
Prepaid Expenses 911 1102 943 898 812
Other Current Assets, Total 204 216 270 1053 1041
Total Assets 117453 131795 127778 118370 145563
Property/Plant/Equipment, Total - Net 12195 13106 13939 13746 15696
Property/Plant/Equipment, Total - Gross 26304 28708 29894 28676 34028
Accumulated Depreciation, Total -14109 -15602 -15955 -14930 -18332
Goodwill, Net 29301 29595 29999 26524 35294
Intangibles, Net 31644 34182 36809 28787 38719
Long Term Investments 1606 2268 11611 10538 9789
Note Receivable - Long Term 948 973 922 624 908
Other Long Term Assets, Total 4849 5953 4825 8647 9594
Total Current Liabilities 28656 30208 33059 28264 29607
Accounts Payable 5146 5553 5403 5424 5556
Accrued Expenses 5334 5100 5336 5058 5105
Notes Payable/Short Term Debt 3635 3606 7319 4844 6430
Current Port. of LT Debt/Capital Leases 2492 2896 2558 2248 3190
Other Current Liabilities, Total 12049 13053 12443 10690 9326
Total Liabilities 58111 64140 71180 62896 66949
Total Long Term Debt 21782 24523 27978 22056 22470
Long Term Debt 20244 22902 26259 20353 22470
Deferred Income Tax 2686 3070 3141 5867 7475
Minority Interest 81 167 68 77 78
Other Liabilities, Total 4906 6172 6934 6632 7319
Total Equity 59342 67655 56598 55474 78614
Common Stock 890 901 913 936 944
Retained Earnings (Accumulated Deficit) 63540 70989 57157 59274 82191
Treasury Stock - Common -92 -48 -53 -80 -69
Unrealized Gain (Loss) -198 206
Other Equity, Total -4798 -4187 -1419 -4656 -4658
Total Liabilities & Shareholders’ Equity 117453 131795 127778 118370 145563
Total Common Shares Outstanding 2119.61 2234.94 2256.82 2265.01 2311.17
Capital Lease Obligations 1538 1621 1719 1703
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 32114 36910 36954 38142 37236
Cash and Short Term Investments 12260 18930 19103 19758 18814
Cash & Equivalents 12000 7517 8726 3625 13852
Short Term Investments 260 11413 10377 16133 4962
Total Receivables, Net 9183 8334 8680 8910 8678
Accounts Receivable - Trade, Net 8916 8066 8422 8643 8409
Total Inventory 7886 7175 6779 6880 6997
Other Current Assets, Total 2785 2471 2392 2594 2747
Total Assets 112241 117453 118464 122910 125218
Property/Plant/Equipment, Total - Net 12348 12195 11731 12206 12861
Goodwill, Net 29481 29301 28668 29113 29636
Intangibles, Net 30451 31644 31888 33367 34853
Long Term Investments 2555 2554 2491 2580 2906
Other Long Term Assets, Total 5292 4849 6732 7502 7726
Total Current Liabilities 30549 28656 28160 27646 29807
Accounts Payable 5426 5146 4693 4969 5083
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 7166 6127 7204 7247 6902
Other Current Liabilities, Total 17957 17383 16263 15430 17822
Total Liabilities 60182 58111 57644 59985 63678
Total Long Term Debt 21985 21782 21235 23784 24373
Long Term Debt 20396 20244 19732 22232 22796
Capital Lease Obligations 1589 1538 1503 1552 1577
Deferred Income Tax 2727 2686 2719 3122 3384
Minority Interest 83 81 78 81 164
Other Liabilities, Total 4838 4906 5452 5352 5950
Total Equity 52059 59342 60820 62925 61540
Common Stock 842 890 890 890 901
Retained Earnings (Accumulated Deficit) 51253 58544 60000 62095 60699
Treasury Stock - Common -36 -92 -70 -60 -60
Total Liabilities & Shareholders’ Equity 112241 117453 118464 122910 125218
Total Common Shares Outstanding 2097.4 2119.61 2150.98 2182.79 2212.58
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 6955 24018 8071 7147 12800
Cash From Operating Activities 14236 15071 13650 13625 14272
Cash From Operating Activities 1873 1807 2088 1852 1783
Amortization 5308 4306 4376 3974 3428
Non-Cash Items 4404 -11714 3842 3369 -2315
Cash Taxes Paid 1975 2342 1833 1876 1506
Cash Interest Paid 696 664 703 793 816
Changes in Working Capital -4304 -3346 -4727 -2717 -1424
Cash From Investing Activities 1468 4208 -13182 -2226 -5591
Capital Expenditures -2671 -2971 -2585 -2257 -2648
Other Investing Cash Flow Items, Total 4139 7179 -10597 31 -2943
Cash From Financing Activities -20562 -16264 -2208 -13627 -4244
Financing Cash Flow Items 55 94 -199 3307 -119
Total Cash Dividends Paid -7506 -7368 -6987 -6645 -6966
Issuance (Retirement) of Stock, Net -10552 -3004 -2094 -5332 -1336
Issuance (Retirement) of Debt, Net -2559 -5986 7072 -4957 4177
Foreign Exchange Effects -32 -266 286 69 -26
Net Change in Cash -4890 2749 -1454 -2159 4411
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 2294 6955 5489 3914 2219
Cash From Operating Activities 2957 14236 10125 5404 1649
Cash From Operating Activities 377 7181 5233 3207 1405
Amortization 1619
Non-Cash Items 1085 4404 3417 2164 918
Cash Taxes Paid 348 1975 1559 1239 633
Cash Interest Paid 123 696 475 308 110
Changes in Working Capital -2418 -4304 -4014 -3881 -2893
Cash From Investing Activities 10621 1468 2935 -2263 9365
Capital Expenditures -470 -2671 -2024 -1442 -859
Other Investing Cash Flow Items, Total 11091 4139 4959 -821 10224
Cash From Financing Activities -9202 -20562 -16568 -11830 -9528
Financing Cash Flow Items -169 55 99 97 22
Total Cash Dividends Paid -7255 -7506 -7506 -7506 -7506
Issuance (Retirement) of Stock, Net -2727 -10552 -7874 -5156 -2448
Issuance (Retirement) of Debt, Net 949 -2559 -1287 735 404
Foreign Exchange Effects 107 -32 -173 -93 -41
Net Change in Cash 4483 -4890 -3681 -8782 1445
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Dodge & Cox Investment Advisor/Hedge Fund 0.9685 20312680 -438692 2023-03-31 LOW
PRIMECAP Management Company Investment Advisor 0.7832 16427035 -767845 2023-03-31 LOW
Franklin Mutual Advisers, LLC Investment Advisor/Hedge Fund 0.3288 6896403 281341 2023-03-31 MED
Loomis, Sayles & Company, L.P. Investment Advisor/Hedge Fund 0.315 6607149 -4338849 2023-03-31 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.2943 6173671 180186 2023-03-31 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 0.2315 4854485 78 2023-03-31 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 0.2128 4462383 -106331 2023-03-31 LOW
BofA Global Research (US) Research Firm 0.1946 4081695 2425777 2023-03-31 LOW
Morgan Stanley Smith Barney LLC Investment Advisor 0.1736 3640036 114140 2023-03-31 LOW
Janus Henderson Investors Investment Advisor/Hedge Fund 0.1722 3610783 -322510 2023-03-31 LOW
Managed Account Advisors LLC Investment Advisor 0.168 3522986 -1190474 2023-03-31 LOW
Schafer Cullen Capital Management, Inc. Investment Advisor/Hedge Fund 0.165 3460003 672290 2023-03-31 LOW
Renaissance Technologies LLC Hedge Fund 0.1453 3047444 -373526 2023-03-31 HIGH
Goldman Sachs & Company, Inc. Research Firm 0.139 2916193 2739477 2023-03-31 MED
Principal Global Investors (Equity) Investment Advisor 0.1302 2730347 264310 2023-03-31 LOW
Parametric Portfolio Associates LLC Investment Advisor 0.1273 2669848 21867 2023-03-31 LOW
Northern Trust Global Investments Investment Advisor 0.1137 2383712 4188 2023-03-31 LOW
UBS Financial Services, Inc. Investment Advisor 0.0898 1883281 -199411 2023-03-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.0896 1878471 -9886 2023-03-31 LOW
Wells Fargo Advisors Research Firm 0.0878 1841280 18484 2023-03-31 LOW

Start a global, multi-asset portfolio with an award-winning platform

Desktop

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Novartis ADR Company profile

Novartis (NVS) provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. Novartis Group companies employ approximately 122,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. The company has been honoured and received numerous awards for progress in research and development, their working environment, and their corporate responsibility activities. Novartis shares are listed and traded on the SIX Swiss Exchange (symbol “NOVN”) as well as on the New York Stock Exchange in the form of ADR (symbol “NVS”). Get all the latest on Novartis Repsg (NVS) share price at Capital.com.
Industry: Pharmaceuticals (NEC)

Lichtstrasse 35
BASEL
BASEL-STADT 4056
CH

Income Statement

  • Annual
  • Quarterly

People also watch

Oil - Crude

73.55 Price
+2.220% 1D Chg, %
Long position overnight fee -0.0201%
Short position overnight fee -0.0019%
Overnight fee time 21:00 (UTC)
Spread 0.03

Gold

1,943.38 Price
-0.270% 1D Chg, %
Long position overnight fee -0.0185%
Short position overnight fee 0.0103%
Overnight fee time 21:00 (UTC)
Spread 0.30

XRP/USD

0.54 Price
-2.160% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.00399

US100

14,510.90 Price
-0.320% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 535.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading